{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-23-026579","form_type":"8-K","ticker":"VCEL","cik":"0000887359","company_name":"Vericel Corp","filed_at":"2023-08-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:36.890750+00:00","generated_at":"2026-06-12T15:54:05.853918+00:00","sec_items":["9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Vericel Q2 revenue $45.9M (+24% YoY); raises FY2023 guidance to $190-197M","bullets":["Total net revenue $45.9M (+24% YoY); MACI $36.3M (+27%), Epicel $9.6M (+17%).","Net loss $5.0M ($0.11 EPS) improved from $9.0M loss in Q2 2022; adjusted EBITDA $4.4M.","Full-year 2023 revenue guidance raised to $190-197M from prior $184-192M; gross margin guidance high-60% maintained.","MACI arthroscopic delivery program on track for 2024 commercial launch; human factors study planned Q3.","Extended exclusive supply agreement with Matricel GmbH for MACI collagen membrane."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-23-026579","json":"https://secwatch.observer/filing/0001628280-23-026579.json","markdown":"https://secwatch.observer/filing/0001628280-23-026579.md","text":"https://secwatch.observer/filing/0001628280-23-026579.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/887359/000162828023026579/0001628280-23-026579-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/887359/000162828023026579/vcel-20230802.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-12T15:54:05.853918+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}